PAYX — Paychex, Inc.

Momentum is positive — RSI 65.63, price 22% above the 200-day SMA — but fundamental sentiment is guarded: consensus is Hold, 6 sell ratings, and management's FY27 EPS guide of $5.90-$6.01 came in conservative. The market is paying up for quality while analysts wait for evidence that Paycor-driven growth turns into durable organic reacceleration.

Revenue grew steadily through FY24-FY25, then jumped in FY26: quarterly revenue went from $1.26-1.44B in FY24 to $1.32-1.51B in FY25 and $1.54-1.81B in FY26. FY26 revenue growth of ~16.9% looks like acceleration, but it includes Paycor; long-term debt jumped from ~$0.80B to ~$4.56B in mid-2025. Organic growth is better described as mid-single-digit. Margins tell a cleaner quality story: operating margin was around 35-44% in the last four quarters, rebounding from a 30.2% Q4 FY25 that was likely dented by acquisition charges. EPS is stable and seasonal; the underlying trend is a high-quality, moderately growing HCM platform.

At $126.48, TTM P/E is 25.76 vs. its own 5-year average of 27.44; P/S is 6.91 vs. 8.26, so the stock is not rich by its own history. Forward P/E on FY27 consensus EPS of $5.96 is about 21.2x — fair for this quality, but not a discount. PEG of 3.82 and analyst targets in the $108-$115 area suggest the current price already embeds optimistic integration assumptions. My independent FCF-based fair value is ~$130.55, meaning the stock is roughly fairly valued.

At ~21x forward earnings, the price is asking Paychex to hit the upper end of FY27 guidance and keep margins near current levels. If it does, $126 is justified; if organic growth stalls or interest income fades, the multiple could compress toward the Street's implied 18-19x forward multiple, putting fair value at $107-$115. In other words, the stock is not discounting a disaster, but it is also not leaving much room for guidance cuts.

As of 2026-08-27, RSI(14) was 65.63 — strong momentum but not yet overbought. Price was 3.99% above the 20-day SMA, 11.92% above the 50-day SMA, and 22.07% above the 200-day SMA, so the trend is firmly up. The stock is extended in the short term; a pullback toward the 20-day (~$122) or 50-day (~$113) would offer a more attractive entry.

• SMB employment and wage growth: Paychex's core market of small businesses is seeing stagnating employment growth and flattening labor-force participation, which pressures net new payroll clients.
• Interest rate trajectory: client fund interest income is a high-margin revenue stream; rate cuts would reduce this tailwind.
• AI/technology disruption in HCM: investors debate whether AI compresses payroll/HCM pricing; Paychex is embedding AI tools to defend pricing power.
• Elevated leverage from the Paycor acquisition: ~$4.56B long-term debt increases sensitivity to rates and integration execution.
• Competitive intensity: ADP, Gusto, and others contest SMB and up-market HCM, pressuring net bookings.

• FQ1 FY27 earnings on 9/30/26: net new bookings, PEO worksite employee growth, and updated guidance.
• Paycor integration milestones and up-market cross-selling traction.
• AI-enabled product launches that could lift revenue per client.
• Any Fed rate easing that changes client fund interest income expectations.

• Organic growth deceleration and Paycor integration execution misses.
• Balance sheet leverage: long-term debt of ~$4.56B and debt-to-equity of 1.24; interest expense could rise if rates stay high.
• Valuation above Street targets: consensus price target $108.80, with 6 sell ratings and 19 holds.
• Labor market downturn reducing payroll volumes and PEO worksite employees.
• Competitive and AI disruption to HCM pricing power.

Paychex is a high-quality defensive compounder: recurring revenue, 74% gross margin, ~39% operating margin, ~20% ROIC, negative accruals, and a 3.8% dividend. The near-term issue is price and growth quality — FY26 growth was boosted by Paycor, organic growth is mid-single-digit, and the stock sits above the consensus target. Long-term constructive, but at $126.48 you are paying full price for a great company; waiting for a dip or clearer organic reacceleration would be a better entry.

Used trailing twelve-month free cash flow of ~$2.32B (sum of the last four reported quarters) and applied a 20x FCF multiple, a reasonable recurring-revenue quality multiple for a business with 74% gross margins, ~20% ROIC, and defensive SMB demand. That yields ~$46.4B of equity value, or ~$130.55 per share based on ~355.7M shares, broadly consistent with ~22x forward EPS.